Citadel Advisors
ACRS icon

Citadel Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Citadel Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.43M Buy
2,249,319
+1,044,038
+87% +$3.52M ﹤0.01% 3488
2025
Q4 		$3.63M Sell
1,205,281
-227,396
-16% -$575K ﹤0.01% 4823
2025
Q3 		$2.72M Buy
1,432,677
+288,871
+25% +$504K ﹤0.01% 5479
2025
Q2 		$1.62M Buy
1,143,806
+21,725
+2% +$29.4K ﹤0.01% 6107
2025
Q1 		$1.72M Buy
1,122,081
+1,066,734
+1,927% +$2.28M ﹤0.01% 5836
2024
Q4 		$137K Sell
55,347
-309,220
-85% -$769K ﹤0.01% 11018
2024
Q3 		$419K Sell
364,567
-510,649
-58% -$626K ﹤0.01% 8644
2024
Q2 		$963K Sell
875,216
-54,787
-6% -$64.4K ﹤0.01% 6660
2024
Q1 		$1.15M Sell
930,003
-4,458,786
-83% -$5.32M ﹤0.01% 6638
2023
Q4 		$5.66M Buy
5,388,789
+2,031,549
+61% +$6.2M ﹤0.01% 3612
2023
Q3 		$23M Buy
3,357,240
+744,166
+28% +$6.36M ﹤0.01% 1715
2023
Q2 		$27.1M Sell
2,613,074
-494,690
-16% -$4.48M 0.01% 1587
2023
Q1 		$25.1M Buy
3,107,764
+2,032,724
+189% +$25.8M 0.01% 1704
2022
Q4 		$16.9M Sell
1,075,040
-43,377
-4% -$698K ﹤0.01% 2141
2022
Q3 		$17.6M Buy
1,118,417
+165,345
+17% +$2.6M ﹤0.01% 2018
2022
Q2 		$13.3M Sell
953,072
-19,128
-2% -$268K ﹤0.01% 2320
2022
Q1 		$16.8M Sell
972,200
-39,572
-4% -$540K ﹤0.01% 2209
2021
Q4 		$14.7M Sell
1,011,772
-51,845
-5% -$785K ﹤0.01% 2440
2021
Q3 		$19.1M Sell
1,063,617
-163,776
-13% -$2.63M ﹤0.01% 2065
2021
Q2 		$21.6M Sell
1,227,393
-99,956
-8% -$2.27M ﹤0.01% 1994
2021
Q1 		$33.4M Buy
1,327,349
+1,286,007
+3,111% +$25.1M 0.01% 1415
2020
Q4 		$267K Buy
41,342
+16,238
+65% +$68.5K ﹤0.01% 9263
2020
Q3 		$65K Buy
+25,104
New +$56.2K ﹤0.01% 9498
2020
Q2 		– Sell
-51,250
Closed -$53K – 9693
2020
Q1 		$53K Buy
51,250
+24,479
+91% +$33.3K ﹤0.01% 9002
2019
Q4 		$51K Sell
26,771
-47,963
-64% -$79.5K ﹤0.01% 8751
2019
Q3 		$80K Buy
74,734
+42,281
+130% +$60K ﹤0.01% 8571
2019
Q2 		$71K Sell
32,453
-156,388
-83% -$852K ﹤0.01% 8631
2019
Q1 		$1.13M Sell
188,841
-365,497
-66% -$2.42M ﹤0.01% 5375
2018
Q4 		$4.1M Sell
554,338
-328,026
-37% -$3.38M ﹤0.01% 3064
2018
Q3 		$12.8M Buy
882,364
+14,134
+2% +$242K 0.01% 1831
2018
Q2 		$17.3M Sell
868,230
-28,607
-3% -$529K 0.01% 1426
2018
Q1 		$15.7M Buy
896,837
+748,422
+504% +$15.9M 0.01% 1322
2017
Q4 		$3.66M Sell
148,415
-93,601
-39% -$2.28M ﹤0.01% 2848
2017
Q3 		$6.25M Buy
242,016
+208,429
+621% +$5.59M ﹤0.01% 2062
2017
Q2 		$911K Sell
33,587
-17,357
-34% -$472K ﹤0.01% 4225
2017
Q1 		$1.52M Buy
+50,944
New +$1.47M ﹤0.01% 3407
2016
Q4 		– Sell
-9,303
Closed -$238K – 7177
2016
Q3 		$238K Buy
+9,303
New +$197K ﹤0.01% 6052

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's ACRS Position: Q1 2026 in Review

Citadel Advisors increased its Aclaris Therapeutics (ACRS) stake by 87% in Q1 2026, buying an estimated $3.52M and bringing the position to 2,249,319 shares worth $8.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3488.

Citadel Advisors first reported a position in ACRS in Q3 2016 and has held it in 37 quarters since. The position peaked at $33.4M in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Citadel Advisors held 2,249,319 shares of Aclaris Therapeutics worth $8.43M as of Q1 2026.
  • Citadel Advisors bought 1,044,038 Aclaris Therapeutics shares in Q1 2026, an estimated $3.52M.
  • Aclaris Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3488 holding.
  • Citadel Advisors first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 37 quarters since.
  • Citadel Advisors's Aclaris Therapeutics position peaked at $33.4M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.